Viking Therapeutics (VKTX) is set to report its first-quarter 2026 earnings, with analysts predicting a loss of 95 cents per share. The company has not recorded any revenue as it lacks a marketed drug, and it previously missed earnings estimates by over 55% in the last quarter.
Key focus areas for investors will include updates on Viking’s pipeline, particularly the late-stage trials for VK2735 aimed at obesity, and its investigational dual amylin and calcitonin receptor agonist candidate. The VANQUISH-1 and VANQUISH-2 studies for VK2735 are currently underway, with data not expected until next year. Additionally, the company plans to file an investigational new drug application for its DACRA candidate by the end of Q1 2026.
Over the past four quarters, Viking has consistently missed earnings estimates, resulting in a negative average surprise of 30.80%. Year-to-date, its shares have increased by 1%, compared to a 3.5% growth in the industry.
